Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Medical device company Penumbra (NYSE:PEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 16.3% year on year to $324.1 million. The company expects the full year’s revenue to be around $1.35 billion, close to analysts’ estimates. Its non-GAAP profit of $0.83 per share was 24.4% above analysts’ consensus estimates.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merit Medical Systems (NASDAQ:MMSI) and the rest of the medical devices & supplies - cardiology, neurology, vascular stocks fared in Q4.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and its peers.
In a sliding market, Penumbra has defied the odds, trading up to $255.82 per share. Its 29.5% gain since October 2024 has outpaced the S&P 500’s 13.6% drop. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including ICU Medical (NASDAQ:ICUI) and its peers.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 13.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which blew past analysts' constant currency revenue, EBITDA, and earnings expectations. Sales grew by 10.8% compared to the previous year due to strong performance in its U.S. thrombectomy business, which surged 27.3%. This strength helped offset a 16.5% decline in international sales, largely due to weaker performance in China. However, despite the strong quarter, full-year revenue guidance for 2025 fell slightly short of expectations.
Looking ahead, the company expects continued growth in its U.S. thrombectomy business, particularly from its computer-assisted vacuum thrombectomy (CAVT) products. That said, international market softness remains a concern.
